Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Brimonidine 0.18% Nanoemulsion
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):